TACSI Trial: Dual or Single Antiplatelet Therapy After CABG in Patients With ACS
Description
In the TACSI trial, researchers evaluated ticagrelor plus aspirin versus aspirin alone in about 2,200 patients who underwent coronary artery bypass grafting (CABG) for acute coronary syndrome (ACS). At 12 months, dual antiplatelet therapy (DAPT) did not reduce major adverse cardiac events compared to aspirin alone. However, it was associated with a higher risk of major bleeding. These findings do not support routine DAPT use post-CABG in ACS patients, though longer-term follow-up is still needed.
In this interview, Drs. Steven E. Nissen and Anders Jeppsson discuss "TACSI Trial: Dual or Single Antiplatelet Therapy After CABG in Patients With ACS".
SUGGESTED MATERIALS:
-
Jeppsson A, James S, Moller CH, et al. Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome. N Engl J Med. Published online September 1, 2025. doi:10.1056/NEJMoa2508026
-
TACSI: Dual or single antiplatelet therapy after CABG in patients with acute coronary syndrome: Reported from ESC Congress 2025 (PCRonline website). 2025. Available at: https://www.pcronline.com/News/Whats-new-on-PCRonline/2025/ESC/TACSI-Dual-or-single-antiplatelet-therapy-after-CABG-in-patients-with-acute-coronary-syndrome. Accessed 10/31/25.
United States
